GO
Loading...

Enter multiple symbols separated by commas

Pharmaceuticals

More

  • TEL AVIV, June 23- Mylan NV chief financial officer John Sheehan will arrive in Israel on Wednesday for a meeting with the head of the Tel Aviv Stock Exchange to discuss a possible listing of its shares if it succeeds in buying Perrigo Co, an industry source said. Mylan has offered to acquire Perrigo for $34 billion in an attempt to fend off a bid from Israel's Teva...

  • LONDON, June 22- European private equity fund CVC and Singaporean sovereign wealth fund Temasek are to buy a controlling stake in the pharmaceutical firm Alvogen, its chairman and chief executive said. Robert Wessman, former CEO of Actavis, founded the New Jersey- based generic drugs firm in 2009.. The transaction is the latest sign of the hectic pace of...

  • LONDON, June 22- GlaxoSmithKline has agreed to sell two meningitis vaccines to Pfizer to satisfy antitrust concerns after its recent acquisition of vaccines business of Novartis. The British drugmaker said on Monday that the total consideration for the sale of its Nimenrix and Mencevax products to Pfizer's Irish unit, including some deferred payments, was...

  • LONDON, June 22- European private equity fund CVC and Singaporean sovereign wealth fund Temasek are to buy a controlling stake in the pharmaceutical firm Alvogen, its chairman and chief executive said. Robert Wessman, former CEO of Actavis, founded the New Jersey- based generic drugs firm in 2009.. The transaction is the latest sign of the hectic pace of...

  • LONDON, June 22- European private equity fund CVC and Singaporean sovereign wealth fund Temasek are to buy a controlling stake in the pharmaceutical firm Alvogen, its chairman and chief executive said. Robert Wessman, former CEO of Actavis, founded the New Jersey- based generic drugs firm in 2009.. The fast-growing company currently has 350 generic products on...

  • Biotech to break out, buy these names: Analyst Friday, 19 Jun 2015 | 3:19 PM ET
    Biotech research

    Biotech is going to break out, RBC Capital Markets' Michael Yee said. There are the names on his buy list.

  • This will change the face of human health: Pro Friday, 19 Jun 2015 | 1:36 PM ET
    This will change the face of human health: Pro

    CNBC's Meg Tirrell dives into how J&J plans to tackle autoimmune disease and why health care professionals say the microbiome "is going to change the face of human health."

  • Suberbug-fighting startup Friday, 19 Jun 2015 | 11:47 AM ET
    Suberbug-fighting startup

    Seres Therapeutics has filed to go public, ticker MCRB (for microbiome). CNBC's Meg Tirrell explains why it has breakthrough therapy designation from the FDA.

  • June 19- China has rejected Gilead Sciences Inc's application for a new patent related to its costly hepatitis C drug Sovaldi, removing a potential barrier to generic versions of the drug there, a U.S. legal group announced on Friday. Gilead still has a patent in China on sofosbuvir, the main ingredient of Sovaldi, a highly effective treatment for hepatitis C which...

  • NEW YORK, June 18- A U.S. appeals court on Thursday once again invalidated a patent held by Teva Pharmaceutical Industries Ltd on its top-selling multiple sclerosis drug Copaxone, clearing the way for the launch of a cheaper, generic version. The decision, by the U.S. Court of Appeals for the Federal Circuit, the nation's top patent tribunal, was a blow to Israel's...

  • U.S. appeals court again invalidates Teva MS drug patent Thursday, 18 Jun 2015 | 11:56 AM ET

    NEW YORK, June 18- A U.S. appeals court on Thursday once again invalidated a patent held by Teva Pharmaceutical Industries Ltd on its top-selling multiple sclerosis drug Copaxone, clearing the way for the launch of a cheaper, generic version.

  • Rite Aid same-store sales miss estimates Thursday, 18 Jun 2015 | 7:16 AM ET

    June 18- Rite Aid Corp, the No.3 U.S. drugstore chain operator, reported slower-than-expected quarterly same-store sales growth as the introduction of new generic drugs hurt pharmacy sales. Net income more than halved to $18.8 million, or 2 cents per share, in the quarter, from $41.4 million, or 4 cents per share, a year earlier. The fall in net income was mainly due to...

  • LONDON/ BEIJING, June 18- A British corporate investigator freed from a Chinese jail last week has accused officials there of deliberately withholding medical treatment to try to force him to confess to a role in a scandal involving drugmaker GlaxoSmithKline Plc. Peter Humphrey and his American wife Yu Yingzeng returned to Britain on Wednesday evening after...

  • New drug compound may beat malaria with single $1 dose Wednesday, 17 Jun 2015 | 1:00 PM ET

    LONDON, June 17- Scientists have discovered a new anti-malarial compound that could treat patients with a single $1 dose, including those with strains of the mosquito-borne disease that are resistant to current drugs. In a vote of confidence for the project, German drugmaker Merck KgAA has secured the right to develop and commercialize the compound, assuming...

  • *Guinea trial last chance to show vaccine efficacy. LONDON, June 17- Drugmakers' plans to conduct vast clinical trials to test and hopefully validate the first Ebola vaccines have been thwarted by success in beating back the deadly epidemic in West Africa. The haemorrhagic Ebola virus has killed more than 11,000 people in Guinea, Sierra Leone and Liberia in an...

  • Allergan buys Kythera in a $2.1B deal Wednesday, 17 Jun 2015 | 8:00 AM ET
    Allergan buys Kythera in a $2.1B deal

    Botox-maker Allergan is buying Kythera Biopharmaceuticals in a $2.1 billion deal.

  • Abbott to vote for Mylan's acquisition of Perrigo Tuesday, 16 Jun 2015 | 9:20 AM ET

    June 16- Abbott Laboratories said it would vote its 14.5 percent stake in Mylan NV in favor of Mylan's proposed acquisition of Perrigo Company Plc. Mylan's latest offer for Perrigo, worth $34.1 billion, is widely seen as an attempt to fend off Teva Pharmaceutical Industries Ltd, the world's biggest maker of generic drugs. Abbott, Mylan's largest shareholder, said...

  • BRUSSELS, June 16- When U.S. trade chief Michael Froman opened talks in 2013 on an EU-U.S. free trade deal he said he was confident it could be reached on "one tank of gas." But as negotiators prepare for their 10th meeting, in Brussels next month, EU officials are complaining that U.S. counterparts are inflexible and the European Parliament is so split on the subject of...

  • Your drug prices too high? Here's who many blame Tuesday, 16 Jun 2015 | 3:00 AM ET
    Pharmaceuticals

    Americans place controlling drug costs at the top of their health-related concerns.

  • *United Tech falls as it looks to exit helicopter business. June 15- Stocks fell on Wall Street on Monday as investors fretted over the consequences of a possible debt default by Greece, but talk of multi-billion dollar healthcare deals buoyed shares in the sector, cutting into the market's loss. After Sunday's breakdown of the cash-for-reform talks between...